The company said: The possible timing of a generic Paxil product remains unclear with the Philadelphia trial still pending and the Chicago decision now moving towards appeal. Dr Garnier says 2004 is a transition cheap paxil year for GSK's product mix, and it should also mark the company's transition from dog to darling. It has been slow to develop a pipeline of new drugs to replace a trio of blockbusters which have lost patent protection. Apotex and GSK's Cheap paxil clash in a Chicago court was the first round of a battle that will conclude in a second case in Philadelphia later this year. It shouldn't take that long for the stock market to wake up cheap paxil to the turnaround, and the company should also have a steady feed of news on the progress of its pipeline of new drugs. GSK says that 2004 is a transition year cheap paxil for its mix of products, and it should also mark the company's transition from dog to darling. Steve Plag, pharmaceuticals analyst at Credit Suisse First Boston, said: This is clearly very good news as it means the second patent case now goes to trial in one of the slowest courts in the US, which should mean no resolution to the Paxil case until the end of 2003 at the earliest. The shares rose 27p to 1,147p. It is a major setback in the company's race to launch enough new drugs to make up for a decline in sales from existing blockbusters. No date has yet been set for the Philadelphia trial, which involves Apotex and four other generic Cheap paxil manufacturers. If they had lost all four patents, Apotex would probably have just launched their product. Glaxo is also pursuing another case against Apotex in Chicago over its patent covering the hemihydrate form of cheap paxil paxil, which expires in 2006. THE WORLD'S No 2 pharmaceuticals giant GlaxoSmithKline has been a dog of an investment since the merger that created it in 2000. Barry Sherman, chief executive, left himself plenty of room to manoeuvre.
The UK giant, run by its chief executive, Jean-Pierre Garnier, said yesterday that it would appeal and said it was currently sticking to its guidance on earnings for 2003. If a generic launch became imminent, GSK would reassess this guidance. The privately-held Apotex played its cards close to its cheap paxil chest yesterday. Yesterday, the metaphor grew cheap paxil up. The drug is also prescribed for panic attacks, anxiety, post-traumatic stress and obsessive compulsive disorder.
It should cheap paxil not take the stock market until then to wake up to the turnaround, and the company should also have a steady feed of news on the progress of its pipeline of new drugs which will rekindle interest.